Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-10-20

    Virtual Booth

    An Enquiry

    Menu

    Sintilimab

    DEVELOPMENTS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 4Tyvyt

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Tyvyt

    Sintilimab

    arrow
    OTS 2025
    Not Confirmed

    Brand Name : Tyvyt

    U.S.A
    arrow
    OTS 2025
    Not Confirmed

    Eli Lilly

    Sintilimab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 418

    2020 Revenue in Millions : 309

    Growth (%) : 35

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Tyvyt

    Sintilimab

    arrow
    OTS 2025
    Not Confirmed

    Brand Name : Tyvyt

    U.S.A
    arrow
    OTS 2025
    Not Confirmed

    Eli Lilly

    Sintilimab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 293

    2021 Revenue in Millions : 418

    Growth (%) : -30

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Tyvyt

    Sintilimab

    arrow
    OTS 2025
    Not Confirmed

    Brand Name : Tyvyt

    U.S.A
    arrow
    OTS 2025
    Not Confirmed

    Eli Lilly

    Sintilimab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 393

    2022 Revenue in Millions : 293

    Growth (%) : 34

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Tyvyt

    Sintilimab

    arrow
    OTS 2025
    Not Confirmed

    Brand Name : Tyvyt

    U.S.A
    arrow
    OTS 2025
    Not Confirmed

    Eli Lilly

    Sintilimab

    Main Therapeutic Indication : Oncology

    Currency : USD

    2024 Revenue in Millions : 526

    2023 Revenue in Millions : 393

    Growth (%) : 34

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF